Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra Miller

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Gastroenterology|November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
American Heart Journal|September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristicsStephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
The Lancet. Diabetes & Endocrinology|May 11, 2026
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialSophia Zoungas, David D'Alessio, Imre Pavo, et al.
The New England Journal of Medicine|December 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen J Nicholls, Imre Pavo, Deepak L Bhatt, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Gastroenterology|November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
American Heart Journal|September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristicsStephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
The Lancet. Diabetes & Endocrinology|May 11, 2026
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialSophia Zoungas, David D'Alessio, Imre Pavo, et al.
The New England Journal of Medicine|December 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen J Nicholls, Imre Pavo, Deepak L Bhatt, et al.
Pageof 5